UPDATE : Tuesday, November 19, 2019
HOME Pharma
Indonesia gave nods to Medytox's hyaluronic acid filler
  • By Lee Han-soo
  • Published 2019.05.28 14:42
  • Updated 2019.05.28 14:51
  • comments 0

Medytox said Tuesday that it has received sales approval for its Neuramis lineup, a series of hyaluronic acid filler, in Indonesia.

Medytox's hyaluronic acid filler Neuramis

Indonesia is one of the world's largest Muslim countries with a rapidly growing economy and is in the spotlight as an essential base for targeting the Islamic market, The demand for aesthetic products such as botulinum toxin and hyaluronic acid filler is increasing in the country along with the growing interest in K-beauty and K-pop.

Neuramis, a hyaluronic acid filler developed by using Medytox's proprietary technology, uses the material listed by the U.S. Food and Drug Administration and European European Directorate for the Quality of Medicines as enhancing safety.

Based on the rising popularity of the product in the home market, Medytox is actively expanding into overseas markets. The company has launched the product in 26 countries and is signing contracts with new partners.

"The fact that Neuramis has entered the demanding Islamic market has proven Medytox's superior R&D capabilities," a company official said. "We will prove the excellence of our fillers in Indonesia, which is leading the Muslim cosmetic market."


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top